199 related articles for article (PubMed ID: 15564137)
41. A novel A33 promoter-based conditionally replicative adenovirus suppresses tumor growth and eradicates hepatic metastases in human colon cancer models.
Cafferata EG; Macció DR; Lopez MV; Viale DL; Carbone C; Mazzolini G; Podhajcer OL
Clin Cancer Res; 2009 May; 15(9):3037-49. PubMed ID: 19336523
[TBL] [Abstract][Full Text] [Related]
42. Oncolytic virotherapy for prostate cancer by E1A, E1B mutant adenovirus.
Satoh M; Wang H; Ishidoya S; Abe H; Moriya T; Hamada H; Arai Y
Urology; 2007 Dec; 70(6):1243-8. PubMed ID: 18158069
[TBL] [Abstract][Full Text] [Related]
43. Carboxyl-terminal repressor domain of MBP-1 is sufficient for regression of prostate tumor growth in nude mice.
Ghosh AK; Steele R; Ray RB
Cancer Res; 2005 Feb; 65(3):718-21. PubMed ID: 15705866
[TBL] [Abstract][Full Text] [Related]
44. Fusion of the BCL9 HD2 domain to E1A increases the cytopathic effect of an oncolytic adenovirus that targets colon cancer cells.
Fuerer C; Homicsko K; Lukashev AN; Pittet AL; Iggo RD
BMC Cancer; 2006 Oct; 6():236. PubMed ID: 17020613
[TBL] [Abstract][Full Text] [Related]
45. Oncolytic replication-competent adenovirus suppresses tumor angiogenesis through preserved E1A region.
Saito Y; Sunamura M; Motoi F; Abe H; Egawa S; Duda DG; Hoshida T; Fukuyama S; Hamada H; Matsuno S
Cancer Gene Ther; 2006 Mar; 13(3):242-52. PubMed ID: 16179928
[TBL] [Abstract][Full Text] [Related]
46. Efficient and selective tumor cell lysis and induction of apoptosis in melanoma cells by a conditional replication-competent CD95L adenovirus.
Fecker LF; Schmude M; Jost S; Hossini AM; Picó AH; Wang X; Schwarz C; Fechner H; Eberle J
Exp Dermatol; 2010 Aug; 19(8):e56-66. PubMed ID: 19725869
[TBL] [Abstract][Full Text] [Related]
47. Androgen receptor-dependent regulation of Bcl-xL expression: Implication in prostate cancer progression.
Sun A; Tang J; Hong Y; Song J; Terranova PF; Thrasher JB; Svojanovsky S; Wang HG; Li B
Prostate; 2008 Mar; 68(4):453-61. PubMed ID: 18196538
[TBL] [Abstract][Full Text] [Related]
48. Prolonged survival of mice with multiple liver metastases of human colon cancer by intravenous administration of replicable E1B-55K-deleted adenovirus with E1A expressed by CEA promoter.
Sagawa T; Takahashi M; Sato T; Sato Y; Lu Y; Sumiyoshi T; Yamada Y; Iyama S; Fukaura J; Sasaki K; Hamada H; Miyanishi K; Takayama T; Kato J; Niitsu Y
Mol Ther; 2004 Dec; 10(6):1043-50. PubMed ID: 15564136
[TBL] [Abstract][Full Text] [Related]
49. Adenovirus-mediated delivery of human IFNgamma gene inhibits prostate cancer growth.
Zhao P; Zhu YH; Wu JX; Liu RY; Zhu XY; Xiao X; Li HL; Huang BJ; Xie FJ; Chen JM; Ke ML; Huang W
Life Sci; 2007 Aug; 81(9):695-701. PubMed ID: 17714738
[TBL] [Abstract][Full Text] [Related]
50. Triple-targeted oncolytic adenoviruses featuring the cox2 promoter, E1A transcomplementation, and serotype chimerism for enhanced selectivity for ovarian cancer cells.
Bauerschmitz GJ; Guse K; Kanerva A; Menzel A; Herrmann I; Desmond RA; Yamamoto M; Nettelbeck DM; Hakkarainen T; Dall P; Curiel DT; Hemminki A
Mol Ther; 2006 Aug; 14(2):164-74. PubMed ID: 16580264
[TBL] [Abstract][Full Text] [Related]
51. Targeted virus replication plus immunotherapy eradicates primary and distant pancreatic tumors in nude mice.
Sarkar D; Su ZZ; Vozhilla N; Park ES; Randolph A; Valerie K; Fisher PB
Cancer Res; 2005 Oct; 65(19):9056-63. PubMed ID: 16204080
[TBL] [Abstract][Full Text] [Related]
52. Potent antitumoral effects of a novel gene-viral therapeutic system CNHK300-mEndostatin in hepatocellular carcinoma.
Li GC; Yang JM; Nie MM; Su CG; Sun LC; Qian YZ; Fang GE; Sham J; Wu MC; Qian QJ
Chin Med J (Engl); 2005 Feb; 118(3):179-85. PubMed ID: 15740644
[TBL] [Abstract][Full Text] [Related]
53. ATRA enhances bystander effect of suicide gene therapy in the treatment of prostate cancer.
Chen W; Yan C; Hou J; Pu J; Ouyang J; Wen D
Urol Oncol; 2008; 26(4):397-405. PubMed ID: 18367126
[TBL] [Abstract][Full Text] [Related]
54. 1alpha,25-Dihydroxyvitamin D3 down-regulates expression of prostate specific membrane antigen in prostate cancer cells.
Serda RE; Bisoffi M; Thompson TA; Ji M; Omdahl JL; Sillerud LO
Prostate; 2008 May; 68(7):773-83. PubMed ID: 18247401
[TBL] [Abstract][Full Text] [Related]
55. Fas ligand delivery by a prostate-restricted replicative adenovirus enhances safety and antitumor efficacy.
Li X; Liu YH; Zhang YP; Zhang S; Pu X; Gardner TA; Jeng MH; Kao C
Clin Cancer Res; 2007 Sep; 13(18 Pt 1):5463-73. PubMed ID: 17875776
[TBL] [Abstract][Full Text] [Related]
56. Application of a tumor suppressor (C-CAM1)-expressing recombinant adenovirus in androgen-independent human prostate cancer therapy: a preclinical study.
Kleinerman DI; Zhang WW; Lin SH; Nguyen TV; von Eschenbach AC; Hsieh JT
Cancer Res; 1995 Jul; 55(13):2831-6. PubMed ID: 7796410
[TBL] [Abstract][Full Text] [Related]
57. Antitumor activity of Ad-IU2, a prostate-specific replication-competent adenovirus encoding the apoptosis inducer, TRAIL.
Jiménez JA; Li X; Zhang YP; Bae KH; Mohammadi Y; Pandya P; Kao C; Gardner TA
Cancer Gene Ther; 2010 Mar; 17(3):180-91. PubMed ID: 19798123
[TBL] [Abstract][Full Text] [Related]
58. Recombinant adenovirus mediated prostate-specific enzyme pro-drug gene therapy regulated by prostate-specific membrane antigen (PSMA) enhancer/promoter.
Zeng H; Wei Q; Huang R; Chen N; Dong Q; Yang Y; Zhou Q
J Androl; 2007; 28(6):827-35. PubMed ID: 17522418
[TBL] [Abstract][Full Text] [Related]
59. A novel attenuated replication-competent adenovirus for melanoma therapy.
Peter I; Graf C; Dummer R; Schaffner W; Greber UF; Hemmi S
Gene Ther; 2003 Apr; 10(7):530-9. PubMed ID: 12646858
[TBL] [Abstract][Full Text] [Related]
60. Evaluation of continuous low dose rate versus acute single high dose rate radiation combined with oncolytic viral therapy for prostate cancer.
Liu C; Zhang Y; Liu MM; Zhou H; Chowdhury W; Lupold SE; Deweese TL; Rodriguez R
Int J Radiat Biol; 2010 Mar; 86(3):220-9. PubMed ID: 20201650
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]